Mark Smith

Mark Smith has extensive experience in the pharmaceutical industry, with a specialized focus on nonclinical development and preclinical research. Mark began their career at GlaxoSmithKline in 2005, where they served as a Project Manager for worldwide nonclinical safety projects until 2009. Mark subsequently joined Amgen as a Scientific Director from 2009 to 2012. Following their time at Amgen, Smith joined Eagle Pharmaceuticals, Inc. as the VP of Preclinical Development from 2012 to 2017. Currently, they hold the position of VP of Nonclinical Development at Spirovant Sciences, Inc. starting from November 2019.

Mark Smith attended Bishop Veseys Grammar School, although the start and end years are not provided. Later on, they pursued a PhD in Genetic Toxicology at the University of Portsmouth, although again, the start and end years are not specified.